Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trialMeg Jardine, Vivekanand Jha, Sradha Kotwal et al.|BMJ|2022Cited by 40
996P Phase II trial of alectinib in ALK-altered solid tumours and NSCLC with negative standard care testing: Australian molecular screening and therapeutics (MoST) substudy 14Frank Lin, D. Thomas, A. Mersiades et al.|Annals of Oncology|2025Cited by 0